Jahnz-Rozyk Karina, Raciborski Filip, Śliwczyński Andrzej M, Kłak Anna, Pinkas Jarosław
Department of Internal Diseases, Pneumonology, Allergology and Clinical Immunology, Military Institute of Medicine, Warsaw, Poland.
Department of the Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.
Postepy Dermatol Alergol. 2017 Dec;34(6):573-579. doi: 10.5114/pdia.2017.70361. Epub 2017 Dec 31.
Epidemiological data on anaphylaxis have been underestimated both in Poland and worldwide.
To evaluate the prevalence of anaphylaxis in Poland, including a classification by gender, age and residential region.
The data used in the analysis were derived from two sources, the National Health Fund records of healthcare services for 2008-2015 (official statistics) and a questionnaire-based survey conducted in 2015 on a sample of 305 allergists practicing in different regions of Poland.
In 2015, 3144 people received treatment for anaphylactic shock (T78.0, T78.2, T80.5, T88.6) with an estimated prevalence rate of anaphylaxis of 8.2 per 100,000 (8.4 for females and 7.9 for males). The highest prevalence rate was found for women aged 50-54 years (14.5 per 100,000). There was a very large difference in the prevalence of anaphylaxis between rural and urban areas (13.1 vs. 0.8 per 100,000). In 2015, the Polish NHF spent PLN 3.5 million (EUR 835,000) on the management of anaphylaxis. Of the allergists surveyed, 73% had been currently managing patients who had experienced anaphylactic shock. The most common causes of anaphylaxis included insect venom (41.4%), food (29.8%) and drugs (17.4%).
A central anaphylaxis registry should be established in Poland. This is the only approach that would allow collecting a wide range of reliable information on the cases, management and consequences of anaphylaxis. Ongoing management of patients who have experienced anaphylactic shock should be improved.
在波兰乃至全球,过敏反应的流行病学数据均被低估。
评估波兰过敏反应的患病率,包括按性别、年龄和居住地区进行分类。
分析中使用的数据来自两个来源,2008 - 2015年国家卫生基金的医疗服务记录(官方统计数据)以及2015年对波兰不同地区305名过敏症专科医生进行的问卷调查。
2015年,3144人接受了过敏性休克治疗(T78.0、T78.2、T80.5、T88.6),估计过敏反应患病率为每10万人8.2例(女性为8.4例,男性为7.9例)。50 - 54岁女性的患病率最高(每10万人14.5例)。农村和城市地区的过敏反应患病率存在很大差异(每10万人分别为13.1例和0.8例)。2015年,波兰国家卫生基金在过敏反应管理方面花费了350万兹罗提(83.5万欧元)。在接受调查的过敏症专科医生中,73%目前正在治疗经历过过敏性休克的患者。过敏反应最常见的原因包括昆虫毒液(41.4%)、食物(29.8%)和药物(17.4%)。
波兰应建立一个中央过敏反应登记处。这是唯一能够收集有关过敏反应病例、管理和后果的广泛可靠信息的方法。应改善对经历过过敏性休克患者的持续管理。